In recent years, various research groups have reported on niPGT-A based on cell-free DNA analysis using spent culture medium.

   Clinical evidence of niPGT-A is also accumulating. As a pioneer in niPGT-A research in Japan, we have provided analysis to more than 20 IVF clinics in Japan.

   In the future, we would like to expand Medi-Seq analysis to the Asia-Pacific region so that all people suffering from infertility can have children with peace of mind. We hope to contribute to your hospital.

Company Name : Genome Clinic Co., Ltd.

Office Location :  Tokatsu Techno 411, 5-4-6, Kashiwa Chiba, Japan

Establishment Date : April 24, 2018

CEO: Hiroki Sonehara M.D., Ph. D

1. We aim to increase the implantation rate by analyzing the DNA of the culture fluid after embryo culture.

2. We also aim to reduce the risk of genetic diseases through whole genome analysis.

1. Medi-Seq evaluates the aneuploidy of the embryo by analyzing the cell-free DNA released from the embryo into the culture medium.

2. By performing cell-free DNA analysis using a next-generation sequencer, it is possible to obtain aneuploidy status that show a high concordance rate with embryo DNA analysis by biopsy (Non-invasive PGT-A; niPGT-A).

1. We offer a new analysis method called Medi-Seq, which does not damage the embryo.

2. Depending on the patient's age and the condition of the embryo, it can be used in combination with conventional analysis methods.

First, we will conduct a free report, and if you are satisfied with the results, we will enter into a contract.

We will provide you with more detailed explanations, data, and papers. Please feel free to contact us.

CEO: Hiroki Sonehara M.D. , Ph.D

Remarks: The contents marked with ＊ are mandatory.